MedTrace Logo

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

NCT03830905 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-11-16

No results posted yet for this study

Summary

The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.

Conditions

  • Influenza
  • Acute Respiratory Viral Infections

Interventions

DRUG

XC221

Participants will receive 200 mg XC221 once a day during 3 days

DRUG

Placebo

Participants will receive Placebo once a day during 3 days

Sponsors & Collaborators

  • RSV Therapeutics LLC

    collaborator INDUSTRY

  • PHARMENTERPRISES LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-07-03
Completion
2019-07-03

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830905 on ClinicalTrials.gov